NASDAQ:CATB
Delisted

Catabasis Pharmaceuticals Stock Forecast

$3.36
+0.195 (+6.16%)
At Close: May 27, 2022
RSI low/high Values: [ 20 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.

FAQ

What is the symbol for Catabasis Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Catabasis Pharmaceuticals is CATB and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Catabasis Pharmaceuticals Stock?
Catabasis Pharmaceuticals holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

How to buy Catabasis Pharmaceuticals Stock?
Catabasis Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Catabasis Pharmaceuticals Stock.

What's the current price of Catabasis Pharmaceuticals Stock?
As of the end of day on the 2022-05-27, the price of an Catabasis Pharmaceuticals (CATB) share was $3.36.

What is the 52-week high and low for Catabasis Pharmaceuticals Stock?
The 52-week high for Catabasis Pharmaceuticals Stock is $10.26 and the 52-week low is $1.20.

What is the market capitalization of Catabasis Pharmaceuticals Stock?
As of the 2022-05-27, the market capitalization of Catabasis Pharmaceuticals is 234.861M.
Click to get the best stock tips daily for free!

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy (DMD); CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia i... CATB Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT